UBS Group’s CM Life Sciences II Inc. Unit CMIIU Stock Holding History

UBS Group’s Portfolio CMIIU Stock Details CMIIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3,735	Closed	-$48K	–	10254
2021 Q1	$48K	Buy	+3,735	New	+$46.9K	﹤0.01%	6614

Other funds holding CMIIU

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WMSA

Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

TCIM

TOMS Capital Investment Management New York $3.81B AUM 26.36% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Islet Management New York $49.1M AUM 17.59% 1-Year Est. Return

UBS Group's CMIIU Position: Q2 2021 in Review

UBS Group sold out of CM Life Sciences II Inc. Unit (CMIIU) in Q2 2021, closing a stake of 3,735 shares — an estimated $48K sold.

UBS Group first reported a position in CMIIU in Q1 2021 and held it in 1 quarter. The position peaked at $48K in Q1 2021. 38 funds tracked by Wall St. Rank hold CMIIU as of Q2 2021.

UBS Group reported no remaining CM Life Sciences II Inc. Unit position as of Q2 2021 after selling out during the quarter.
UBS Group sold 3,735 CM Life Sciences II Inc. Unit shares in Q2 2021, an estimated $48K.
UBS Group first reported a position in CM Life Sciences II Inc. Unit in Q1 2021 and held it in 1 quarter.
UBS Group's CM Life Sciences II Inc. Unit position peaked at $48K in Q1 2021.
38 funds tracked by Wall St. Rank held CM Life Sciences II Inc. Unit as of Q2 2021.

Based on UBS Group's 13F filing for Q2 2021, filed 13 Aug 2021.